May 19, 2016 5:50pm

 

The resistance, we are seeing is just another thread of weakness as expressed by sentiment and conveyed by algorithms

 

Pre-open indications: 3 hit and 2 miss

 

Do you care what happened today, you should … because it has implications to Friday's sector activity?  

Subscribe:  http://www.regmedinvestors.com/create-account    

 

 

There is one thing that everyone needs, and that's interpretation and translation of intelligence, not just news or information - we get too much!

  • To that end, I report a matrix of variables designed for investor’s consideration concerning the stem, cell and gene therapy and regenerative medicine portfolio to track and monitor its pricing metric;

 

 

U.S. stocks closed lower Thursday after comments from New York Fed President William Dudley and the latest Fed minutes increased prospects of a rate hike as soon as June.

The NASDAQ closed DOWN -26.59 or -0.56% to 4,712.53 and the DOW closed DOWN -91.22 or -0.52% to 17,435.40.

 

 

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector – the advance/decline line scenario of our 43 covered companies.   

  • Opened negative with an A/DL of 18/25 and 0 flat;

 

  • The mid-day stayed negative with an A/DL of 4/28 with 1 flat;

 

  • The closing bell remained negative with A/DL of 5/35 with 3 flats

 

 

Henry’omics:

Sector stocks opened negative, stayed negative at the mid-day and closed negative.

  • “Some of us think holding on makes us strong; but sometimes it is letting go” … Hermann Hesse.

Yesterday’s upside triggered dissolution of value because it was based on WHAT …?

  • As far as the SCGT&RM sector goes, I think “our” universe is riding the carousel up, down – basically round and round as one up day gets offset by the down!

Volatility as measured by the VIX jumped to 16.7 from 15.3 – jumping a forward sell-off.

  • Where is all the “de-risking” of sector assets; uncertainty continues at an all-time high … just look at the recent attempts by a couple of companies to finance.

Forget death crosses; it’s for some a death knell to the future!

  • For the record, what is a 'Death Cross' – a crossover resulting from a stock's long-term moving average breaking above its short-term moving average or support level?

Also, remember an option expiration day is close …!

 

 

A pre-open indication batting stats – 3 hit and 2 miss:

  • Applied Genetic Technologies (AGTC) closed DOWN -$0.55 – hit;
  • bluebird bio (BLUE) closed DOWN -$0.56 – hit;
  • Cellectis SA (CLLS) closed DOWN -$0.08 – miss;
  • Juno Therapeutics (JUNO) closed DOWN -$0.38 – hit;
  • Spark Therapeutics (ONCE) closed UP +$5.94 – miss;

 

 

Out and about:

Cesca Therapeutics (KOOL) closed UP +$1.60 to $3.61 on the basis of one (1) patient treated.

  • The patient was able to return to normal life two weeks after the AMIRST procedure, and the main findings of the study showed a significant improvement in the Left Ventricular Ejection Fraction from 35% at patient's initial assessment to 60.3% at 24 months post-AMIRST intervention.
  • One patient does NOT make a TRIAL success … but, it has made the company a target for a sell-off!

 

  • Be ready for a downward SLIDE …

 

 

Today's Bottom Line:

  • Sentiment is so negative, that’s exactly what we will be subjected to – for this quarter!

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

  • Thursday traded 16.7;
  • Wednesday traded at 15.3;
  • Tuesday traded below 15;
  • Monday traded below 14.6;
  • Friday closed near 14.5;
  • Last, Thursday near 14;

 

 

Who was leading the declines – to of the bottom 5?

  • uniQure (QURE) closed down -$0.62 to $12.06;
  • bluebird bio (BLUE) -$0.56 to $38.83;
  • Applied Genetic technology (AGTC) -$0.55 to $15.2;
  • Juno Therapeutics (JUNO) -$0.38 to $39.30;
  • Regenxbio (RGNX) closed down -$0.33 to $11.92;

 

 

Who was UP – top 5:

  • Spark Therapeutics (ONCE) closed up +$5.94 to $47.17;
  • Cesca Therapeutics (KOOL) +$1.60 to $3.61;
  • Mesoblast (MESO) +$0.01 to $6.83;
  • Stemline (STML) +$0.01 to $5.47;
  • Neuralstem (CUR) +$0.0021 to $0.326

 

 

Who was flat?

  • Capricor (CAPR) at $3.30;
  • StemCells (STEM) at $2.67;
  • ReNeuron (RENE.L) at $3.375;

 

 

Most active sector stocks + and -:

  • Northwest Bio (NWBO) -9.91%;
  • Pluristem (PSTI) -7.24%;
  • Histogenics (HSGX) -6.60%;
  • Caladrius Biosciences (CLBS) -6.32%;
  • Biostage (BSTG) -5.37%;

versus …

  • Cesca Therapeutics (KOOL) +79.60%;
  • Spark Therapeutics (ONCE) +14.41%;
  • Neuralstem  (CUR)+0.65%;
  • Stemline (STML) +0.18%;
  • Mesoblast (MESO) +0.15%

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.